GSK1120212: Phase I data

GlaxoSmithKline reported data from a 3-part, open-label, dose-escalation, U.S. Phase I trial of once-daily oral GSK1120212 for 21 days in 162 patients with solid tumors or lymphoma. In 20 evaluable pa...